Dear Editor,
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with an overall 5-year survival rate of less than 10%. Between 20 and 30% of PDAC cases are resectable at diagnosis; however, patients’ post-operative survival periods vary widely, irrespective of active therapeutic interventions.1 Therefore, extensive efforts have been made to identify biomarkers that may identify patients with an improved prognosis. Although profound local immune suppression had been implicated in PDAC progression and poor patient survival, a prognostic marker that can directly and functionally read immune evasion in situ is not yet available.
Cell-in-cell structures (CICs) refer to the presence of one or more cells inside a host cell, which are coordinately driven by a set of core elements including adherens junction, acytomyosin and mechanical ring,2 generally leading to inner cell death.3 CICs are prevalent in a wide range of human tumors and have different subtypes, including homotypic CICs formed between tumor cells, and heterotypic CICs formed via internalization of immune cells into tumor cells.3 Therefore, the heterotypic CICs might serve as a novel mechanism of immune evasion that conceivably promotes cancer progression.4 However, the contribution of different CICs, especially heterotypic CICs, to patient prognosis has yet to be established. This study aims to explore the feasibility of using subtyped CICs as a kind of functional biomarker predicting patient survival in PDAC.
In total, 410 specimens from 147 pair-matched cancer and non-malignant tissues and 116 cancer-only tissues, were included in this study. Out of these, 300 specimens, consisting of 147 case-matched non-malignant pancreas controls and 153 cancer tissues (note: only 125 cancer tissues were included into the final analysis due to missing information), were plotted on TMA stained by “EML” multiplex method5 (Supplementary Fig. S1) and used as the discovery cohort. The additional 110 validation specimens were collected from the First Affiliated Hospital of Sun Yat-sen University, and, detected by immunohistochemistry staining (Supplementary Fig. S2). The clinical characteristics of the 235 patients included in the final analysis were generally comparable between the discovery and validation cohorts (Supplementary Table S1 and Supplementary Fig. S3).
The CICs in the discovery cohort were minimally detected in non-malignant tissues (15/147) but were prevalent in cancer tissues (97/125) (p < 0.0001) (Fig. S1a–e). Four CIC subtypes were identified (Fig. 1a): tumor cells inside tumor cells (TiT), lymphocytes (CD45+) inside tumor cells (CDs−) (LiT), tumor cells inside macrophages (TiM), and macrophages inside tumor cells (MiT). The subtype of TiT constituted the majority (~70%) of overall CICs (oCICs) (Fig. 1b). Identity analysis indicated that tumor cells were the major engulfer (96.4%) over macrophages (3.6%) (Fig. 1c), and that both tumor cells (73.4%) and immune cells (7.3% CD45+ and 19.3% CD68+) could be internalized as inner cells (Fig. 1d). A similar CIC profile was identified in the validation cohort (Fig. 1b–d).
In the discovery cohort, homotypic TiT was more frequently detected in tissues of older patients (45/70 for <60 years old vs. 45/55 for ≥60 years old, p = 0.03); however, this was not confirmed in the validation dataset. Heterotypic MiT and L/MiT (for LiT plus MiT) tended to be more frequently present in tumor tissues of a late TNM stage (35/109 vs. 11/16, p = 0.005) and low tumor differentiation (37/85 vs. 25/40, p = 0.048), respectively, which were confirmed in the validation cohort. When combining the discovery and validation datasets, the presence of homotypic TiT also demonstrated a significant association with late TNM stage (p = 0.0032) (Supplementary Table S2a–c). These results are consistent with the notion that later stage tumor cells more frequently engage in cannibalistic activities.
Univariate analysis revealed that tumor grade, TNM stage, lymph node (LN) invasion, and distant metastasis were significantly associated with postoperative survival in all 3 cohorts. Of these traditional variables, TNM stage was likely, and expectedly, the most consistent and representative survival classifier across the 3 cohorts. Notably, the presence of oCICs, LiT, MiT and L/MiT was also associated with a shorter OS across the 3 cohorts. The adverse prognostic role of heterotypic CICs may have been specific for CICs of the tumor cell engulfer (L/MiT) as the presence of TiM, the heterotypic CIC subtype of macrophage engulfer, did not significantly impact patient survival (Fig. 1e and Supplementary Fig. S4, Supplementary Table S3–4).
For multivariate survival analysis, we included all of the variables identified in univariate analysis (grade, TNM stage, LN invasion, distant metastasis, oCIC, TiT, LiM, MiT, and L/MiT) into the Cox proportional hazards model. Unexpectedly, TNM stage was not an independent prognostic factor (HR = 1.642, 95%CI: 0.897–3.006, p = 0.108) in the discovery cohort, whereas L/MiT was the strongest risk factor for a poor prognosis, with a death hazard ratio of 1.850 (95% CI: 1.175–2.915, p = 0.008). And the heterotypic L/MiT was the only variable that was consistently identified as an independent prognostic factor across 3 cohorts of patients (Fig. 1f), suggesting that L/MiT could be a dominant contributor to a poor prognosis.
To directly evaluate L/MiT’s contribution to prognosis, we constructed a nomogram that incorporated all 5 independent prognostic factors identified, each of which was assigned a score on a point scale based on its predictive power from the multivariate analysis. As shown in Fig. 1g, h, despite the fluctuations in the performance of the traditional variables across 3 cohorts, L/MiT consistently dominated over all the traditional factors in predicting patient survival, and incorporating L/MiT improved the prediction performance at the time point of 14.0 months. We also calculated the AUC values at earlier survival time points, which reported similar results as shown in Supplementary Table S5.
To further analyze whether L/MiT preferentially affects a specified portion of patients, we stratified the combined cohort of patients by TNM stage or histological grade for multivariate analysis. Traditional variables identified in univariate analysis (grade, N, M, and TNM stage) except for the stratifiers, and all types of CICs, were examined by Cox proportional hazards model. As shown in Supplementary Table S6–7 and Fig. 1i (first line), L/MiT was the only prognostic factor that could independently predict postoperative OS, specifically in patients of an early TNM stage. The selectivity of L/MiT was also applied to patients stratified by grade, age and sex, but not tumor site, N stage, or M stage (Supplementary Table S12–14), where L/MiT is a highly selective predictor of a poor outcome in young, female and low grade patients while TNM stage demonstrated little patient preference (Fig. 1i and Supplementary Table S8–11). The nomogram construction and AUC analysis confirmed that at 14 months, L/MiT was a selective prognostic classifier that predicts decreased survival in young female patients with resectable PDAC (Fig. 1j–m and Supplementary Fig. S6).
In summary, this study reported the first subtype-based CIC profiling in human PDAC, and identified oCICs and its heterotypic subtypes (LiT, TiM, and L/MiT) as valuable prognostic markers in predicting patient survival in a specified group. L/MiT was identified as a potent adverse prognostic marker impacting young female patients with early-stage PDAC. Our work also supports functional pathology with CIC profiling as a novel input for traditional pathology. Despite these implications, our study presents several limitations which were described detailly in the Discussion section of the Supplemental files.
References
Johnson, B. A. 3rd et al. Strategies for increasing pancreatic tumor immunogenicity. Clin. Cancer Res 23, 1656–1669 (2017).
Wang, M. et al. Mechanical ring interfaces between adherens junction and contractile actomyosin to coordinate entotic cell-in-cell formation. Cell Rep. 32, 108071 (2020).
Huang, H., Chen, Z. & Sun, Q. Mammalian cell competitions, cell-in-cell phenomena and their biomedical implications. Curr. Mol. Med 15, 852–860 (2015).
Zhang, X. et al. Subtype-based prognostic analysis of cell-in-cell structures in early breast cancer. Front Oncol. 9, 1–12 (2019).
Huang, H. et al. Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining. Oncotarget 6, 20278–20287 (2015).
Acknowledgements
The authors appreciate the academic support from the AME Pancreatic Cancer Collaborative Group, and professional advice from Dr. Hua Zhang (Peking University Third Hospital, China) for statistics, Dr. Ryan M. Thomas (University of Florida, USA), Dr. Roberta Elisa Rossi (Università degli Studi di Milano, Italy), Dr. Paul Zarogoulidis (“Bioclinic“ Private Hospital, Thessaloniki, Greece), Dr. Benedetto Ielpo (University Hospital of Leon, Spain), Dr. Nicolas Jonckheere (Univ Lille, CNRS, Inserm, France), Dr. Marco Falasca (Curtin University, Australia), and Dr. Faustino Mollinedo (Consejo Superior de Investigaciones Científicas, Spain). This work was supported by the National Key Research & Development Program of China (2016YFC1303303 to Q.S., 2018YFA0900804 to Y.Z., 2019YFA09003801 to Q.S.), and the National Natural Science Foundation of China (81572799 to H.H., 31671432 to Q.S., 31770975 to X.W., 81972483 to M.H.).
Author information
Authors and Affiliations
Contributions
Concept and design: Q.S. and H.H.; Staining and imaging: Q.S., M.H., B.Z., and Z.N.; Figures: Q.S. and M.H.; Acquisition and analysis of data: H.H., M.H., Q.S., X.W., B.Z., and Y.Z.; Data interpretation and drafting of the paper: H.H., Q.S., M.H., and P.C.; Statistical analysis: H.H., M.H., P.C., and W.L.; Funding: H.H., Q.S., X.W., Y.Z., and M.H. All authors have read and approved the final paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, H., He, M., Zhang, Y. et al. Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma. Sig Transduct Target Ther 5, 246 (2020). https://doi.org/10.1038/s41392-020-00346-w
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-020-00346-w
This article is cited by
-
Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma
Cell Death & Disease (2024)
-
Tumor malignancy by genetic transfer between cells forming cell-in-cell structures
Cell Death & Disease (2023)
-
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
Frontiers of Medicine (2023)
-
Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer
BMC Cancer (2022)
-
Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y
Biology Direct (2022)